ABSTRACT
Recently, few reports have described a serious condition linked to SARS-CoV-2 that mimics Kawasaki disease called multisystem inflammatory syndrome, especially in children (MIS-C) and young adults. In this work, we report on a severe form of MIS in a young female adult previously infected by SARS-CoV-2. She was treated by plasmapheresis with albumin and steroids, however outcome was fatal. We discuss the pathogenesis of this rare and life threatening entity and suggest some therapeutic regimen. This syndrome should not be misdiagnosed with an infectious or a drug induced cutaneous rash in the current context of COVID-19 pandemic.
Subject(s)
COVID-19 , Mucocutaneous Lymph Node Syndrome , Systemic Inflammatory Response Syndrome , Adult , COVID-19/complications , Female , Humans , Mucocutaneous Lymph Node Syndrome/diagnosis , Mucocutaneous Lymph Node Syndrome/drug therapy , Pandemics , SARS-CoV-2ABSTRACT
Recently, few reports have described a serious condition linked to SARS-CoV-2 that mimics Kawasaki disease called Multisystem inflammatory syndrome, especially in children (MIS-C) and young adults. In this work, we report on a severe form of MIS in a young female adult previously infected by SARS-CoV-2. She was treated by plasmapheresis with albumin and steroids, however outcome was fatal. We discuss the pathogenesis of this rare and life threatening entity and suggest some therapeutic regimen. This syndrome should not be misdiagnosed with an infectious or a drug induced cutaneous rash in the current context of COVID-19 pandemic.
ABSTRACT
We report the case of a previously healthy patient who was severely affected by COVID-19 and developed torsade de pointes after hydroxychloroquine-azithromycin administration. Critically ill COVID-19 patients have multiple abnormalities that lead to an unsteady state in heart electricity, and can potentiate hydroxychloroquine cardiotoxicity. In light of this clinical observation, and until the efficacy of this association is proven, we plead against its use in critically ill COVID-19 patients.